Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients
Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib : an active agent only in non progressive patients.
Imatinib is a standard treatment for advanced/metastatic GIST and in adjuvant setting. Anaemia is frequently observed in patients with advanced GIST, and is one of the most frequent side effects of imatinib with grade 3–4 anaemia in 10% of patients. Whether EPO treatment is useful in the management of GIST patients receiving imatinib treatment is unknown.
A retrospective study of EPO treatment in GIST patients receiving imatinib was undertaken in 4 centres. Thirty four patients received EPO treatment among the 319 GIST patients treated with imatinib in clinical trials or with compassionate use between 2001 and 2003. The efficacy of EPO on the anaemia of patients with GIST treated with imatinib was analyzed.
There were 18 males and 16 females with a median age of 59 years. Median WHO-PS was 1. Primary tumour sites were mainly gastric (32%) and small bowel (29%). Sites of metastases were mainly liver (82%) and peritoneum (79%). The median delay between the initiation of imatinib treatment and EPO was 58 days (range 0–553). Median haemoglobin (Hb) level prior to EPO was 9 g/dL (range 6,9-11,8) and 11,7 g/dL (range 6,8-14,4) after 2 months. An increase of more than 2 g/dL was observed in 18 (53%) of patients. None of the 7 patients who progressed (PD) under imatinib treatment (400 mg/day) experienced HB response, as compared to 66% (18/27) of the remaining patients (PR + SD) (p = 0,002). Primary tumour site, liver metastases, peritoneal metastases, age, gender did not correlate with HB response to EPO. Response to EPO was observed in 2/11 patients receiving high-dose imatinib (800 mg/day) vs 16/23 of others. Using logistic regression, only PD before EPO treatment was retained as a predictive factor for EPO response.
EPO enables to increase Hb in most anaemic GIST patients who do not progress under imatinib, but not in patients with progressive disease.
- Demetri, GD, von Mehren, M, Blanke, CD (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours. N Engl J Med 347: pp. 472-480 CrossRef
- Verweij, J, van Oosterom, A, Blay, JY (2003) Results from an EORTC STBSG phase II study. Eur J Cancer 39: pp. 2006-2011 CrossRef
- Verweij, J, Casali, P, Zalcberg, J, LeCesne, A, Peter, R, Blay, J-Y, Issels, R, van Oosterom, A, Hogendoorn, P, Van Glabbeke, M, Judson, I (2004) Improved progression free survival in gastro-intestinal stromal tumours with high dose Imatinib. Results of a randomized phase III study of the EORTC, ISG and AGITG. Lancet 364: pp. 1127-1134 CrossRef
- Blay, JY, Le Cesne, A, Ray-Coquard, I, Bui, B, Duffaud, F, Delbaldo, C, Adenis, A, Viens, P, Rios, M, Bompas, E, Cupissol, D, Guillemet, C, Kerbrat, P, Fayette, J, Chabaud, S, Berthaud, P, Perol, D (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumours comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 25: pp. 1107-1113 CrossRef
- Le Cesne, A, Ray-Coquard, I, Bui, BN, Adenis, A, Rios, M, Bertucci, F, Duffaud, F, Chevreau, C, Cupissol, D, Cioffi, A, Emile, JF, Chabaud, S, Pérol, D, Blay, JY (2010) for the French Sarcoma Group. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 10: pp. 942-949 CrossRef
- Dematteo, RP, Ballman, KV, Antonescu, CR, Maki, RG, Pisters, PW, Demetri, GD, Blackstein, ME, Blanke, CD, von Mehren, M, Brennan, MF, Patel, S, McCarter, MD, Polikoff, JA, Tan, BR, Owzar, K (2009) American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373: pp. 1097-1104 CrossRef
- Blay, JY, Bonvalot, S, Casali, P, Choi, H, Debiec-Richter, M, Dei Tos, AP, Emile, JF, Gronchi, A, Hogendoorn, PC, Joensuu, H, Le Cesne, A, McClure, J, Maurel, J, Nupponen, N, Ray-Coquard, I, Reichardt, P, Sciot, R, Stroobants, S, van Glabbeke, M, van Oosterom, A, Demetri, GD (2005) GIST consensus meeting panelists. Consensus meeting for the management of gastrointestinal stromal tumours. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. Ann Oncol 16: pp. 566-578 CrossRef
- Van Glabbeke, M, Verweij, J, Casali, PG, Simes, J, Le Cesne, A, Reichardt, P, Issels, R, Judson, IR, van Oosterom, AT, Blay, JY (2006) Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur J Cancer 42: pp. 2277-2285 CrossRef
- Bokemeyer, C, Aapro, MS, Courdi, A, Foubert, J, Link, H, Osterborg, A, Repetto, L, Soubeyran, P (2007) European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43: pp. 258-270 CrossRef
- Bohlius, J, Schmidlin, K, Brillant, C, Schwarzer, G, Trelle, S, Seidenfeld, J, Zwahlen, M, Clarke, M, Weingart, O, Kluge, S, Piper, M, Rades, D, Steensma, DP, Djulbegovic, B, Fey, MF, Ray-Coquard, I, Machtay, M, Moebus, V, Thomas, G, Untch, M, Schumacher, M, Egger, M, Engert, A (2009) Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373: pp. 1532-1539 CrossRef
- Cortes, J, O’Brien, S, Quintas, A (2004) Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer 100: pp. 2396-2402 CrossRef
- Van Glabbeke, M, Verweij, J, Casali, PG, Le Cesne, A, Hohenberger, P, Ray-Coquard, I, Schlemmer, M, van Oosterom, AT, Goldstein, D, Sciot, R, Hogendoorn, PC, Brown, M, Bertulli, R, Judson, IR (2005) Initial and late resistance to imatinib in advanced gastrointestinal stromal tumours are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 23: pp. 5795-5804 CrossRef
- Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Clinical Sarcoma Research
- Online Date
- September 2012
- Online ISSN
- BioMed Central
- Additional Links
- Author Affiliations
- 1. Hôpital La Timone, Marseille, France
- 2. Institut Gustave Roussy, Villejuif, France
- 4. Centre Léon Bérard, Department of Medecine, French Sarcoma Group (GSF-GETO), European Organisation for Research and Treatment of Cancer (EORTC), University Claude Bernard Lyon I, Lyon, France
- 3. Centre René Gauducheau, Nantes, France